Proangiogenic Features of Perinatal Tissue-Derived Stem Cells in Cardiovascular Disease Therapy
Author:
Tao Hongyan,Li Zongjin
Publisher
Springer Singapore
Reference110 articles.
1. Du W, Tao H, Zhao S, He ZX, Li Z. Translational applications of molecular imaging in cardiovascular disease and stem cell therapy. Biochimie. 2015;116:43–51.
https://doi.org/10.1016/j.biochi.2015.06.021
.
2. Nair V, Madan H, Sofat S, Ganguli P, Jacob MJ, Datta R, et al. Efficacy of stem cell in improvement of left ventricular function in acute myocardial infarction—MI3 Trial. Indian J Med Res. 2015;142(2):165–74.
https://doi.org/10.4103/0971-5916.164245
.
3. Roura S, Pujal JM, Bayes-Genis A. Umbilical cord blood for cardiovascular cell therapy: from promise to fact. Ann N Y Acad Sci. 2012;1254:66–70.
https://doi.org/10.1111/j.1749-6632.2012.06515.x
.
4. Roura S, Soler-Botija C, Bago JR, Llucia-Valldeperas A, Fernandez MA, Galvez-Monton C, et al. Postinfarction functional recovery driven by a three-dimensional engineered fibrin patch composed of human umbilical cord blood-derived mesenchymal stem cells. Stem Cells Transl Med. 2015;4(8):956–66.
https://doi.org/10.5966/sctm.2014-0259
.
5. Galvez-Monton C, Prat-Vidal C, Roura S, Soler-Botija C, Bayes-Genis A. Update: innovation in cardiology (IV). Cardiac tissue engineering and the bioartificial heart. Rev Esp Cardiol (Engl Ed). 2013;66(5):391–9.
https://doi.org/10.1016/j.rec.2012.11.012
.